| 000 | 01758 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515135742.0 | ||
| 264 | 0 | _c20090217 | |
| 008 | 200902s 0 0 eng d | ||
| 022 | _a1365-2133 | ||
| 024 | 7 |
_a10.1111/j.1365-2133.2008.08865.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWarren, R B | |
| 245 | 0 | 0 |
_aBiologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. _h[electronic resource] |
| 260 |
_bThe British journal of dermatology _cJan 2009 |
||
| 300 |
_a162-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aCost-Benefit Analysis _xeconomics |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPsoriasis _xeconomics |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aSalvage Therapy _xmethods |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited Kingdom |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aBrown, B C | |
| 700 | 1 | _aLavery, D | |
| 700 | 1 | _aAshcroft, D M | |
| 700 | 1 | _aGriffiths, C E M | |
| 773 | 0 |
_tThe British journal of dermatology _gvol. 160 _gno. 1 _gp. 162-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2133.2008.08865.x _zAvailable from publisher's website |
| 999 |
_c18276052 _d18276052 |
||